Cleerly vs. HeartFlow: Cardiac AI Valuations Decoded

The trajectory of pre-IPO cardiac AI valuations is a critical area of analysis for venture capitalists and industry analysts. The recent $329 million funding secured by Cleerly, comprising a $223 million Series C and a $106 million extension in December 2024, prompts a direct comparison to HeartFlow, which completed its initial public offering in August 2025. This substantial capital infusion, coupled with Cleerly’s CERTAIN multicenter trial data and FDA clearance, raises a pertinent question for the market: is Cleerly IPO-ready, and what factors truly underpin such valuations in the evolving landscape of healthcare AI venture capital?

Deconstructing Cleerly’s Funding and Clinical Validation

Cleerly’s impressive funding rounds position it as a significant player in the cardiac AI diagnostic space. The $329 million total, anchored by its Series C and subsequent extension, demonstrates robust investor confidence. This financial backing is a primary indicator of market readiness, signaling that the company has secured the necessary runway for continued development and commercialization efforts. However, funding alone is insufficient to guarantee a successful IPO or long-term market durability.

A key differentiator for Cleerly, and a critical factor in its valuation, is its commitment to rigorous clinical validation. The company’s multicenter trial data, particularly from the CERTAIN study, provides a strong evidence base for its technology. In the highly regulated healthcare sector, especially for SaMD (Software as a Medical Device) products like cardiac AI diagnostics, clinical outcomes data is paramount. Investors, particularly VCs and growth equity firms, increasingly scrutinize the quality and generalizability of clinical evidence as a predictor of commercial success and reimbursement pathway clarity. This commitment to multicenter trials de-risks the investment, providing tangible proof of efficacy that resonates with both clinicians and payers.

Furthermore, Cleerly’s FDA clearance is a non-negotiable prerequisite for market entry and scalability. While the specific pathway (likely a 510(k) clearance, given the nature of many cardiac AI diagnostics) is not detailed, the clearance itself confirms regulatory compliance and allows for commercial deployment. This regulatory hurdle, once cleared, signifies a critical milestone in a company’s journey towards potential public offering. For HeartFlow, its pre-IPO trajectory similarly highlighted the importance of both substantial funding and regulatory approvals, paving the way for its market presence.

Comparing Trajectories: Cleerly, HeartFlow, and Hello Heart

When assessing Cleerly’s IPO readiness, drawing parallels to HeartFlow’s journey is instructive. HeartFlow, a pioneer in applying AI to cardiac diagnostics, demonstrated that a combination of significant venture capital, robust clinical data (including large-scale trials demonstrating impact on patient management and outcomes), and regulatory approvals were essential for attracting pre-IPO valuations. The market timing, specifically the post-HeartFlow IPO landscape, also plays a role, as investors now have a more defined benchmark for cardiac AI companies seeking public markets.

However, a crucial piece of the valuation puzzle for Cleerly, as with many pre-IPO companies, remains undisclosed: revenue. While strong funding, multicenter trial data, and FDA clearance are positive indicators, the absence of publicly available revenue figures introduces a degree of uncertainty for analysts and potential investors. The ability to demonstrate a scalable revenue model, particularly one supported by outcomes-based contracting or clear reimbursement pathways, is often the final linchpin for a successful IPO. Analysis of revenue models in digital health Without this transparency, investors must rely more heavily on the strength of clinical evidence and market potential.

In this context, Hello Heart offers a parallel, albeit distinct, pre-IPO cardiac AI trajectory. While Cleerly focuses on advanced diagnostic imaging, Hello Heart centers on remote patient monitoring (RPM) and outcomes-based contracting for cardiovascular health. Hello Heart’s model underscores the importance of demonstrating not just clinical efficacy, but also clear economic value and integration into existing payer systems. This focus on outcomes-based contracting and direct payer engagement can significantly enhance funding durability, as it aligns incentives and provides a clearer path to sustainable revenue streams. While a peer to Cleerly in the broader cardiac AI space, Hello Heart’s approach highlights that diverse strategies can lead to durable funding, provided there is a clear path to value realization for stakeholders.

Regulatory Landscape and Clinical Rigor as Value Drivers

The regulatory environment, particularly the FDA 510(k) Pathway, is a foundational element in the valuation of cardiac AI companies. Most SaMD in this domain leverage the 510(k) route, demonstrating substantial equivalence to a predicate device. This pathway is generally quicker than the De Novo classification for truly novel devices without a predicate, making it attractive for companies aiming for faster market entry. However, achieving 510(k) clearance still requires rigorous data submission and adherence to quality management systems (QMS), such as ISO 13485. FDA guidance on 510(k) submissions

The FDA’s Center for Devices and Radiological Health (CDRH) plays a pivotal role in shaping the landscape for AI in healthcare. Their evolving guidelines, including discussions around Predetermined Change Control Plans (PCCP) for adaptive AI/ML devices, are crucial for long-term product viability. Companies that proactively engage with regulatory bodies and design their products with GMLP (Good Machine Learning Practice) principles in mind demonstrate a mature approach that de-risks future regulatory hurdles. The involvement of institutions like Mayo Clinic in clinical trials, or as early adopters, further validates the technology’s clinical utility and strengthens its position for regulatory review and market acceptance.

The shift towards real-world evidence (RWE) is also gaining traction, supplementing traditional randomized controlled trials (RCTs). While multicenter trials like CERTAIN are gold standard, RWE derived from large datasets can further bolster the case for clinical utility and cost-effectiveness, appealing to both regulatory bodies and payers. This comprehensive approach to evidence generation is increasingly expected by sophisticated investors who understand the complexities of bringing novel medical technologies to market.

Key Takeaways for Future Cardiac AI IPOs

The journey of Cleerly and the precedent set by HeartFlow offer invaluable insights for VCs and industry analysts scrutinizing the next wave of cardiac AI IPOs. Durable funding trajectories for AI health companies are not solely predicated on the size of funding rounds but are deeply intertwined with demonstrable clinical outcomes and established payer contracts. The five factors identified for Cleerly’s IPO readiness, strong funding, multicenter trial data, FDA clearance, transparent revenue models (or a clear path to them), and favorable market timing, form a comprehensive framework for evaluation.

Companies that can clearly articulate their data moat, navigate the patent thicket, and demonstrate a robust QMS will command higher valuations. The ability to move beyond initial FDA clearance to securing CPT codes (Category I or III) and potentially NTAP (New Technology Add-On Payment) for reimbursement is a powerful indicator of commercial viability. As the healthcare AI venture capital market matures, the emphasis will increasingly shift from technological novelty to proven clinical utility, economic value, and operational scalability, ensuring that only the most robust and evidence-backed companies achieve IPO success and long-term market leadership. Report on digital health reimbursement trends